Zealand Pharma Highlights Participation in Healthcare Conference
Zealand Pharma Highlights Participation in Healthcare Conference
Zealand Pharma A/S is excited to announce its upcoming participation in the Cantor Global Healthcare Conference. Known for its focus on innovative peptide-based medicines, the company will showcase its dedication to advancing healthcare solutions.
The Upcoming Conference Details
Scheduled for a notable date in September, Chief Medical Officer David Kendall, MD, will take part in a fireside chat. This event is part of a broader effort to foster discussions around advancements in healthcare and biotechnology.
Fireside Chat Timing
The chat is set for 9:10 a.m. ET, aligning perfectly with the interests of investors and stakeholders in the biotechnology sector. Attending the conference allows Zealand Pharma to engage with its audience, share insights, and discuss the future of therapeutic innovations.
Online Presence and Accessibility
For those unable to attend in person, Zealand Pharma will facilitate a live audio webcast. This transparency not only demonstrates the company’s commitment to stakeholders but also provides valuable insights to a wider audience.
Accessing the Webcast
The webcast will be available through the company’s official channels, ensuring that key updates and discussions are accessible even to those who cannot attend the event. A recording will also be made available post-event for future reference.
About Zealand Pharma A/S
Zealand Pharma A/S, trading on Nasdaq under the ticker ZEAL, is at the forefront of biotechnology innovation. With a remarkable portfolio, including over ten drug candidates in clinical development, the company is committed to advancing peptide-based therapies.
Recent Achievements
Zealand Pharma has celebrated significant milestones, with two of its drug candidates already hitting the market. Additionally, three candidates are in late-stage development, reinforcing its reputation as a leader in the peptide medicines space.
Investor Relations and Contacts
The company maintains robust relationships within the pharmaceutical community and invests in strong partnerships for the development and commercialization of its products. For investors interested in the company’s direction or seeking more information, direct contacts are available.
Contact Information
Adam Lange, the Investor Relations Officer at Zealand Pharma, is available for inquiries. Similarly, Anna Krassowska, PhD, serves as the Vice President of Investor Relations and Corporate Communications, catering to both investor and media interests.
Frequently Asked Questions
What is Zealand Pharma’s primary focus?
Zealand Pharma specializes in the discovery and development of peptide-based medicines aimed at enhancing therapeutic options in various medical fields.
Who will represent Zealand Pharma at the conference?
David Kendall, MD, the Chief Medical Officer, will represent Zealand Pharma during the fireside chat at the conference.
How can I access the live webcast?
The live webcast can be accessed through Zealand Pharma's official website, where it will also be archived for those who miss the live event.
What are the key accomplishments of Zealand Pharma?
Zealand Pharma has successfully positioned more than ten drug candidates in clinical development, with notable offerings already available in the market.
Who should I contact for investor relations inquiries?
For any investor relations questions, Adam Lange is the designated contact, along with Anna Krassowska for broader communications.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.